Medtronic Stock Falls After Q4 Earnings and M&A Deal: Here's Why

Medtronic Plc's MDT reported Q4 FY23 sales of $8.54 billion, up 5.6% Y/Y as reported and organic, ahead of expectations, beating the consensus of $8.25 billion.

Q4 revenue growth acceleration was broad-based, driven by procedure volume recovery, supply improvements, and innovative product introductions.

Medtronic's heart device unit sales increased 12% Y/Y (+6.5% organic) to $3.2 billion. 

Spine & neurosurgery product segment sales increased 4.8% Y/Y (+6%) to $2.4 billion.

Diabetes revenue of $595 million decreased by 0.3% (+3%).

The Medical Surgical Portfolio sales decreased 0.3% (+4.8% organic) to $2.22 billion. 

The adjusted EPS of $1.57 exceeded the consensus of $1.56.

Dividend: Medtronic has announced a dividend increase to $0.69/share quarterly compared to $0.68 paid in the prior quarter.

Guidance: The company expects FY24 organic revenue growth of 4.5%-4.5%. Currency headwinds could affect FY24 sales by approximately $110-$210 million.

Medtronic expects adjusted EPS of $5.00-$5.10, compared to the consensus of $5.20.

M&A: Medtronic has agreed to acquire Korea-based EOFlow Co Ltd, manufacturer of the EOPatch device — a tubeless, wearable, and fully disposable insulin delivery device

Upon closing of the transaction, Medtronic will work to integrate the EOPatch device with its next-generation sensor and clinically proven Meal Detection Technology algorithm currently offered in its MiniMed 780G system.

The total consideration would be KRW 971 billion ($738 million). The deal is expected to close in the second half of the calendar year 2023.

The transaction is expected to be less than 1% dilutive to Medtronic's adjusted EPS in each of the first three years and neutral to accretive after that. 

Price Action: MDT shares are down 3.95% at $85.03 during the premarket session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsM&ANewsGuidanceDividendsHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!